Provided by Tiger Trade Technology Pte. Ltd.

Bio-Rad Laboratories

355.57
-22.1400-5.86%
Post-market: 355.570.00000.00%16:15 EDT
Volume:264.58K
Turnover:95.51M
Market Cap:9.52B
PE:43.06
High:379.67
Open:373.87
Low:353.30
Close:377.71
52wk High:396.23
52wk Low:236.73
Shares:26.76M
Float Shares:22.32M
Volume Ratio:0.95
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.26
EPS(LYR):27.85
ROE:3.11%
ROA:1.66%
PB:1.33
PE(LYR):12.77

Loading ...

Bio Rad Laboratories Inc: are Reaffirming Our Full-Year Outlook

THOMSON REUTERS
·
Aug 05

Bio-Rad Laboratories: on July 31, Initiated Restructuring Plan to Improve Operating Performance - SEC Filing

THOMSON REUTERS
·
Aug 05

Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate

Benzinga Earnings
·
Aug 05

Bio-Rad Q2 Net Income USD 371.4 Million

Reuters
·
Aug 05

Bio-Rad Q2 EPS Usd 13.85

THOMSON REUTERS
·
Aug 05

Bio-Rad Q2 Adjusted EPS USD 2.62 VS. Ibes Estimate USD 1.75

THOMSON REUTERS
·
Aug 05

Bio-Rad Outlook FY Adjusted Revenue Growth -3 to 0.5%

THOMSON REUTERS
·
Aug 05

Bio-Rad Laboratories: Expects Non-Gaap Operating Margin of About 10.0% to 12.0% for the FY 2026

THOMSON REUTERS
·
Aug 05

Press Release: Bio-Rad Reports Second-Quarter 2026 Financial Results

Dow Jones
·
Aug 05

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

GlobeNewswire
·
Jul 30

Central Bank of Jordan Selects BIO-key for National Biometric Authentication Initiative

GlobeNewswire
·
Jul 28

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

GlobeNewswire
·
Jul 28

Bio-rad to Report Q2 2026 Results, Host Conference Call

Reuters
·
Jul 23

Bio-rad to Report Second-quarter 2026 Financial Results on Tuesday, August 4, 2026

THOMSON REUTERS
·
Jul 23

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

GlobeNewswire
·
Jul 23

BIO-UV Group Holds H1 Revenue Stable and Confirms 2026 Growth Targets

TIPRANKS
·
Jul 23

NYSE Order Imbalance 81654.0 Shares on Sell Side

THOMSON REUTERS
·
Jul 21

Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate

Simply Wall St.
·
Jul 12

BIO-key Regains Compliance with Nasdaq Listing Rules; Nasdaq Trading Resumes on Wednesday, July 8th

GlobeNewswire
·
Jul 07

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

GlobeNewswire
·
Jul 02